management of aes from amivantamab and lazertinib for egfr-m nsclc
Published 2 weeks ago • 60 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
3:50
amivantamab plus lazertinib is a new standard for egfr-mutant nsclc
-
6:15
mariposa: longer-term follow-up of amivantamab & lazertinib in egfr-m nsclc
-
2:03
amivantamab and lazertinib in treatment-naïve egfr-mutant nsclc
-
5:18
expert video report on amivantamab in combination therapy for 1l treatment in egfrm, advanced nsclc
-
16:45
amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve egfrm nsclc
-
1:27
mariposa: follow-up of lazertinib with amivantamab or osimertinib in egfr-m nsclc
-
4:55
amivantamab lazertinib administration method may affect outcomes in advanced nsclc
-
12:21
泰格莎失敗後該怎麼辦?繼續標靶藥物?化學治療?免疫治療?
-
10:59
lung cancer stage 4: egfr l858r & e709k positive after 13months of taking osimertinib-tagrisso
-
14:59
肺癌四代靶向药的解读
-
9:54
amivantamab combo with lazertinib favourable in post-osimertinib egfr-mutant nsclc
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
0:41
skippirr: reducing amivantamab-related irrs in egfr-m nsclc
-
9:02
amivantamab plus lazertinib for egfr-mutant lung cancer following progression on osimertinib
-
0:47
the future of amivantamab and lazertinib in egfr-mutant nsclc
-
3:17
phase iii mariposa: amivantamab lazertinib vs osimertinib in egfr-mutated nsclc
-
3:16
mariposa-2: second interim os of amivantamab and chemotherapy in egfr-m nsclc
-
1:09
current and novel treatment approaches for first-line egfr-m nsclc
-
2:08
mariposa: mechanisms of resistance to 1l amivantamab lazertinib in pts with egfr-m nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
3:27
paloma-3: subcutaneous vs intravenous amivantamab lazertinib in refractory egfr-mutated nsclc
-
2:21
amivantamab, an egfr-met bispecific antibody, in combination with lazertinib in advanced egfr nsclc